Liraglutide biosimilar(Glenmark Pharmaceuticals)

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug NameLiraglutide biosimilar(Glenmark Pharmaceuticals)
Drug Alias NameLirafit™
ClassificationBiologics > Biosimilar
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2024/01/03
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGlenmark Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A